The use of aspirin in breast cancer
The use of aspirin after combined treatment of early breast cancer does not reduce the likelihood of recurrence.
There is evidence of the effectiveness of aspirin and other NSAIDs in the prevention of certain malignant diseases (eg, colorectal cancer). Reducing the risk of cancer, as well as recurrence, with the use of these drugs was also observed in animal studies. However, the results of a double-blind phase III study of more than 3,000 patients at high risk for HER2-negative breast cancer showed no reduction in recurrence rates among those prescribed aspirin for 5 years compared with those who did not receive it.
You can read more here.
We thank E.F. Satirova, head of the department of antitumor drug treatment, oncologist K+31 West, for the up-to-date information.
